Sign in
Taking peopleNo phase

Looking back at human anaplasmosis cases after tick bites in Alsace

Reviews past anaplasmosis cases in Alsace to describe symptoms, test results and patterns.

Key facts

Who runs it
University Hospital, Strasbourg, France
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace
Status
Recruiting
People taking part
100 people, planned
Started
2 Oct 2024
Planned end
Feb 2026
Type of study
Observational
Record updated
31 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had human anaplasmosis, a tick-borne bacterial infection, in Alsace. It looks back at past cases.

Age
18 years and older
Sex
All sexes
Disease stage
Infection with Anaplasma confirmed by a PCR test
Biomarker or test result
A PCR test (a lab test that finds the germ's genetic material) confirming Anaplasma infection

Main reasons for not taking part

  • People who refuse to take part in the study cannot join

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Adult subjct (≥18 years)
  • Presenting with a PCR-confirmed infection of Anaplasma

Who cannot take part

  • Refusal to participate in the study

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace. This infection is responsible for clinical manifestations that are most often mild, including fever, headache, and myalgia, occurring 2 to 3 weeks after a tick bite. However, this infection can be accompanied by potentially serious or even fatal complications, including severe cytopenias, acute respiratory distress syndrome, septic shock, severe neurological disorders, hemorrhagic manifestations, macrophage activation syndrome, and multiple organ failure. Mortality is variable and appears to be higher in American studies, where it is around 4%. Treatment is well-established and relies on doxycycline, which is highly effective. Although a few cases have been described in France, these are mostly isolated cases or short series of cases, whereas Belgium, Poland, and Slovenia have reported numerous cases. Thus, there is a lack of data on French cases, and given that Alsace is in a region with a high prevalence of tick-borne diseases, data is needed to better understand the epidemiology and to better identify suspected cases in order to provide appropriate care.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace: a Retrospective and Multicenter Study
Plain-language title
Looking back at human anaplasmosis cases after tick bites in AlsaceGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
31 December 2025